Achillion Pharmaceuticals Inc logo

ACHN - Achillion Pharmaceuticals Inc Share Price

$6.76 0.0  0.0%

Last Trade - 27/01/20

Sector
Healthcare
Size
Mid Cap
Market Cap £772.2m
Enterprise Value £646.8m
Revenue £n/a
Position in Universe th / 6308
Bullish
Bearish
Unlock ACHN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACHN Revenue Unlock ACHN Revenue

Net Income

ACHN Net Income Unlock ACHN Revenue

Normalised EPS

ACHN Normalised EPS Unlock ACHN Revenue

PE Ratio Range

ACHN PE Ratio Range Unlock ACHN Revenue

Dividend Yield Range

ACHN Dividend Yield Range Unlock ACHN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACHN EPS Forecasts Unlock ACHN Revenue
Profile Summary

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated August 5, 1998
Public Since October 26, 2006
No. of Shareholders: 58
No. of Employees: 56
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 140,046,647
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACHN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to ACHN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.